Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02360397 · ClinicalTrials.gov registry record · Phase 2
Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
A Phase 2 study of Myocardial Ischemia and Ventricular Premature Complexes, sponsored by Kent Hospital, Rhode Island.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT02360397: Completed Phase 2 study of Myocardial Ischemia and Ventricular Premature Complexes, sponsored by Kent Hospital, Rhode Island.
NCT02360397 is a Phase 2 study of Myocardial Ischemia and Ventricular Premature Complexes that has completed, run by Kent Hospital, Rhode Island. The registered enrollment target is 6 participants, below the 2,138-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02360397, a Phase 2 study of Myocardial Ischemia and Ventricular Premature Complexes, has completed, sponsored by Kent Hospital, Rhode Island.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether ranolazine has beneficial effects on cardiac ischemia through reduction of premature ventricular contraction burden.
Primary Outcome
The change in percentage of PVC burden after taking Ranolazine 1000mg twice daily for 30 days
Conditions Studied
Interventions
- DRUG ranolazine
Study Locations (1)
Rhode Island
- Kent Hospital - Warwick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-02-23 |
| Phase | Phase 2 |
What the finished NCT02360397 record still lists
NCT02360397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 2,138-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Myocardial Ischemia appearing as the primary indexed condition, and to 1 intervention - of which ranolazine is the first listed.
NCT02360397 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT02360397 about?
NCT02360397 is a clinical study titled "Ranolazine Mediated PVC Reduction in Ischemic Heart Disease". The purpose of this study is to determine whether ranolazine has beneficial effects on cardiac ischemia through reduction of premature ventricular contraction burden.
What is the current status of trial NCT02360397?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2014-12. Estimated completion is 2018-02-23.
What conditions does trial NCT02360397 study?
This clinical trial studies the following conditions: Myocardial Ischemia, Ventricular Premature Complexes.
What interventions are being tested in trial NCT02360397?
The interventions under investigation include: ranolazine (DRUG).
Who is sponsoring clinical trial NCT02360397?
This trial is sponsored by Kent Hospital, Rhode Island, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02360397 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Ischemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02360397's enrollment target sits among peer trials
6 30th of 29 the lowest of 29 other Myocardial Ischemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Ischemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACT34-CMI -- Adult Autologous CD34+ Cells
COMPLETED · Phase 2
-
Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
-
Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease
COMPLETED · Phase 2
-
Bright Light Exposure in Surgical Patients
RECRUITING · NA
-
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia